Danny Analytics provides real-time aggregated analyses of structured and unstructured health data with integration of registries, external clinical and drug databases, etc. The application delivers insight on how specific factors influence patient outcomes and the effectiveness of regimens for value-based care.
A statistical summaries tool to provide immediate insight into real-world hospital data
A powerful analytic tool to provide time-to-event analyses of filtered patient groups. Kaplan-Meier curves of survival, tracking with predefined survival endpoints:
A comprehensive and effective tool for full clinical pathway of patient(s), procedures, diagnostics and treatment outcomes.
Danny Analytics enables better tracking and evaluation of real-world data to uncover newly approved drug adaptation patterns, market access, and drug effectiveness.
Cost-effectiveness analyses and ICER calculations. In support of HTA submissions. In support of reimbursement renewals. Clinical data for market assess.
Danny Analytics provides real-time access to patients’ eligibility for clinical trials of interest. Using pre-defined inclusion and exclusion criteria, eligible patients are automatically updated for improved efficiency and reduced costs in patient recruitment. Reduces the time and cost of clinical trial enrolment.
Physicians are given an immediate summary of healthcare data – in aggregate or of individual patients – for delivery of high-quality cost-effective care. Danny Analytics provides statistical data, benchmarks and real-world evidence of therapeutics. Predictive analytics of patient outcomes.
Validated and high-quality patient data through machine-learning enabled data-quality pipelines.
Enables oncologists to make informed decisions based on large amount of important information.
Calculates treatment outcomes and provides physicians with access to clinically important endpoints, such as overall survival (OS), progression-free survival (PFS), objective response rate (ORR), etc.
Due to rising costs of therapeutics, there is an urgent need to move away from fee-for-service toward performance-based care. As such, evaluating effectiveness of drugs and comparators based on clinical and real-world evidence are critically important. Danny Analytics provides pharmacoeconomic models to evaluate and extrapolate survival and costs based on clinical and local data for cost-effectiveness analyses. This gives budgetary predictability and assessment of effectiveness within public budget spending. Value-based reimbursement. Population health analyses. Stronger cost controls and reduced risk.
Experience Danny and its benefits for your organization.Request a Demo